Trial Review

The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12618000782235
Ethics application status
Approved
Date submitted
7/05/2018
Date registered
9/05/2018
Date last updated
20/12/2018
Date data sharing statement initially provided
20/12/2018
Date results provided
20/12/2018
Type of registration
Retrospectively registered

Titles & IDs
Public title
Pharmacokinetic study of two orally formulated combinations of acetaminophen and ibuprofen (Maxigesic Rapid vs Maxigesic 325) in healthy volunteers under fasting conditions
Scientific title
Randomized, single dose, two-way crossover Open Label Study to Evaluate and compare the Pharmacokinetic parameters of 325 mg Acetaminophen and 97.5mg Ibuprofen film coated tablet, after an oral administration of 30 healthy adults under fasting conditions.
Secondary ID [1] 294808 0
Not applicable
Universal Trial Number (UTN)
U1111-1213-5406
Trial acronym
Not applicable
Linked study record
Not applicable

Health condition
Health condition(s) or problem(s) studied:
Pain relief 307729 0
Condition category
Condition code
Anaesthesiology 306795 306795 0 0
Pain management

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Maxigesic® Rapid (Treatment A)- Acetaminophen 325 mg and Ibuprofen 97.5mg
Single Dose: Oral administration of three film coated tablets with 240 ml of water under fasting conditions (subjects will be fasted-abstain from all liquids and food except water for at least 10 hours overnight before dosing and for 4 hours after dosing)
The dose will be taken under the supervision of the site study staff and the dosing time will be recorded on the site source document
The washout period is at least 3 days between the two treatment periods.

Intervention code [1] 301120 0
Treatment: Drugs
Comparator / control treatment
COMBOGESIC® (Maxigesic® 325) tablets (Treatment B)- Acetaminophen 325mg and Ibuprofen 97.5mg
Single Dose: Oral administration of three film coated tablets with 240 ml of water under fasting conditions.
Control group
Active

Outcomes
Primary outcome [1] 305781 0
To evaluate and compare the pharmacokinetic parameters (Cmax, AUC0-t, AUC0-inf, Tmax, Kel and t1/2el) between test and reference products under fasting conditions
Timepoint [1] 305781 0
Blood samples (14) were collected before dose (0.00) and at 5 minutes (0.083 hours), 15 minutes (0.25 hours), 30 minutes (0.50 hours), 45 minutes (0.75 hours) and 1.00, 1.25, 1.50, 2.00, 3.00, 6.00, 8.00, 10.00 and 12.00 hours post dose. The total volume of blood draws did not exceed 420 ml.
Secondary outcome [1] 346522 0
To compare the safety and tolerability of test and reference products under fasting conditions.
An acute safety evaluation will be performed during each study period by recording spontaneously reported adverse events and by clinical assessments, including measurements of vital signs (blood pressure, heart rate, respiratory rate) and body temperature.
These measurements will be done at screening as well as prior, during and after each dosing period.
Vital signs will be measured pre-dose and approximately at 0.50, 1.00, 1.50, 2.00, 3.00, 4.00, 6.00 and 12.00 hours after study drug administration. Body temperature will be measured before dosing and approximately at the following times after dosing: 4th and 12th hour. Vital signs may be taken at other times if deemed necessary.
At screening and at the end of each study period an additional blood sample will be taken for haematology, biochemistry and serological assessment (only in screening).
Known NSAID adverse effects (i.e. GI ulceration, indigestion/stomach pain, GI bleeding, bronchospasm, water retention, renal failure, skin reactions and thromboembolic events), and known adverse effects of acetaminophen (i.e. clinical evidence of hepatotoxicity) will be compared between groups.
Adverse events will continue to be assessed up to 7 days after the last dose of the study medication by spontaneous reporting and at a final follow-up phone call.
Timepoint [1] 346522 0
Safety will be evaluated during each study period and for 7 days following study drug administation

Eligibility
Key inclusion criteria
Healthy subjects, males and females aged 18 to 50 years of age. Females must be sterile or using adequate contraception. Participants must not have taken any prescription medications for at least 14 days or over-the-counter medications and herbal remedies for at least 7 days before the start of each study phase and for the duration of the study, with the exception of oral contraceptives and the study medication.
All subjects must be deemed healthy on the basis of a medical history, physical exam (including vital signs and 12-lead ECG recording), urinalysis, and blood biochemical, serological and haematological examinations.
Minimum age
18 Years
Maximum age
50 Years
Sex
Both males and females
Can healthy volunteers participate?
Yes
Key exclusion criteria
Female who are pregnant or nursing (not applicable for male subjects).
Female of childbearing potential who are unwilling to take adequate contraceptive precautions, i.e., a hormonal contraceptive, an intrauterine device, double-barrier method, or abstinence. A woman of childbearing potential is defined as any female who is less than 2 years post-menopausal or has not undergone a partial or total hysterectomy or surgical sterilisation, e.g. bilateral tubal ligation, bilateral oophorectomy (not applicable for male subjects).
Female of childbearing potential who are unwilling to undergo a urine pregnancy test (not applicable for male subjects).
Have an alcohol intake in excess of 14 units per week for females and 21 units per week for males.
Have a history of drug abuse or positive test results for drug abuse during screening.
Unwilling to abstain from smoking throughout the whole duration of the study
Unable and refuse to abstain the used prescription drugs (not including oral contraceptives and the study medication) within 14 days prior to study drug administration or have used over-the-counter drugs or herbal products within 7 days prior to study drug administration and during the study.
Unable and refuse to abstain the use of vitamins for nutritional purposes within 2 days prior to study drug administration until the last study sample is collected in each period.
Unable and refuse to abstain to consume grapefruit containing foods or beverages within 7 days or caffeine containing foods or beverages within 24 hours prior to study drug administration until the last study sample is collected in each period.
Currently, or in last 80 days, participating in a clinical trial involving another study drug.
Have donated blood or blood products within 60 days prior to study drug administration.
Have a clinically significant abnormal laboratory test (as determined by the Principal Investigator), Hb, PCV and RBC indices (MCV, MCH and MCHC) tests which deviated outside the 5% of reference range or laboratory results of liver or kidney function tests (creatinine, urea and ALP will be accepted if below reference range, total protein and albumin accepted if above reference range) are outside the reference range.
Be on a special diet (for example is vegetarian).
Unable and refuse to abstain to engage in strenuous exercise within 24 hours prior to study drug administration until the last sample is collected in each study period.
Have at screening examination a pulse outside the normal range of (60-100 beat per minute) or a body temperature outside the normal range of (35.0-37.2 oC) or a respiratory rate outside the normal range of (14-20 breath per minute) or a sitting blood pressure less than 100/60 mm Hg or more than or equal to 140/90 mm Hg.
Unable and refuse to abstain to consume any beverages or food containing alcohol for 24 hours prior to study drug administration until the last study sample is collected in each period.
Have a history of difficulties in swallowing or any gastrointestinal disease which could affect the drug absorption.
Suffering from any other diseases or condition which, in the opinion of the investigator, means that it would not be in the participant’s best interests to participate in this study.
Subject is a heavy smoker (more than 10 cigarettes per day).
Acute infection within one week preceding study drug administration.
Have any history of allergy or hypersensitivity to ibuprofen, aspirin or other NSAID.
Have any history of allergy or hypersensitivity to acetaminophen. Have severe known haemopoetic, renal or hepatic disease, immunosuppression.
Have a history of gastric ulceration, indigestion, stomach pain or GI bleeding or bleeding disorders.
Currently suffering from dehydration through diarrhoea and/or vomiting.
Have a history of severe asthma defined as previous steroid treatment or hospital admission within the last 5 years.
Have a history of severe hypertension, ventricular tachycardia or other cardiac disease.
Have a history of long-standing insulin dependent diabetes mellitus.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Allocation is not concealed
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Simple randomization using a randomization table created by computer software
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Crossover
Other design features
Not applicable
Phase
Phase 1
Type of endpoint/s
Bio-equivalence
Statistical methods / analysis
PK Analysis:
AUC0-t: The area under the plasma concentration versus time curve from time zero to the last measurable concentration, as calculated by the linear trapezoidal method.
AUC0-inf: The area under the plasma concentration versus time curve, from zero to infinity. AUC0-inf is calculated as the sum of the AUC0-t plus the ratio of the last measurable concentration to the elimination rate constant (Ct/Kel).
Cmax: Maximum measured plasma concentration directly obtained from the experimental data of plasma concentration versus time curves, without interpolation
Kel: Apparent first-order elimination or terminal rate constant calculated from a semi-log plot of the plasma concentration versus time curve. The parameter will be calculated by linear least-squares regression analysis using the last three (or more) non-zero plasma concentrations.
Tmax: Time of maximum measured plasma concentration. If the maximum value occurs at more than one point, Tmax is defined as the time of the first occurrence
T1/2el: Time required for the plasma drug concentration to decrease by one half. This value is estimated from the elimination rate constant (Kel) calculated from the slope of the linear relationship between the loge concentration and time during the terminal elimination phase
The actual times of blood sampling will be used for these calculations as per internal SOPs, DMU-001
Missing drug concentration data (value below LLOQ, missing value) will be treated as follows:
-Any missing concentration values are not included in the pharmacokinetic calculations.
-Values below LLOQ are treated as zero for all pharmacokinetic and statistical analyses.
Descriptive statistics, including the means, standard deviations, standard error of the mean and coefficient of variation, shall be reported for the plasma concentrations. For pharmacokinetic parameters, arithmetic means, standard deviations, standard error of the mean, minimum, median, maximum, coefficient of variation, inter-quartile ranges and geometric means shall be reported.

Safety Analysis:
AEs will be collected for all randomized participants and will be listed with type of AE, severity and relationship for each treatment group, using the safety population. Adverse events data will be summarized for each formulation using frequencies and percentages (% of participants with each specific AE).
The haematology and biochemistry data collected pre-study and after each study period will be summarized descriptively using means, medians, standard deviations, ranges and frequencies and percentages as appropriate. Individual values outside normal ranges and considered clinically significant will be individually listed. Comparisons of the haematology and biochemistry measures associated with each treatment may be compared between treatments using repeated measures by ANOVA using Systat program.

Recruitment
Recruitment status
Completed
Date of first participant enrolment
Anticipated
Actual
4/04/2018
Date of last participant enrolment
Anticipated
Actual
8/04/2018
Date of last data collection
Anticipated
Actual
17/04/2018
Sample size
Target
30
Accrual to date
Final
32
Recruitment outside Australia
Country [1] 10377 0
Jordan
State/province [1] 10377 0
Amman, Jordan

Funding & Sponsors
Funding source category [1] 299405 0
Commercial sector/Industry
Name [1] 299405 0
AFT Pharmaceuticals Ltd
Country [1] 299405 0
New Zealand
Primary sponsor type
Commercial sector/Industry
Name
AFT Pharmaceuticals Ltd.
Address
Level 1, 129 Hurstmere Road, Takapuna, Auckland, 0622, New Zealand
Country
New Zealand
Secondary sponsor category [1] 298693 0
None
Name [1] 298693 0
Address [1] 298693 0
Country [1] 298693 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 300308 0
IRB of IPRC (International Pharmaceutical Research Center)
Ethics committee address [1] 300308 0
Ethics committee country [1] 300308 0
Jordan
Date submitted for ethics approval [1] 300308 0
07/03/2018
Approval date [1] 300308 0
15/03/2018
Ethics approval number [1] 300308 0
ACIB-T2018/16

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 83238 0
Dr Dr. Majdi Abu Awida, M.D
Address 83238 0
IPRC (International Pharmaceutical Research Center)
1 Queen Rania Street - Sport City Circle, Amman 11196 Jordan
Country 83238 0
Jordan
Phone 83238 0
+962-6-5627648
Fax 83238 0
+962-6-5627654
Email 83238 0
[email protected]
Contact person for public queries
Name 83239 0
Jennifer Zhang
Address 83239 0
AFT Pharmaceuticals ltd.
Level 1, 129 Hurstmere Road, Takapuna, Auckland, 0622 New Zealand
Country 83239 0
New Zealand
Phone 83239 0
+ 64 9 488 0232
Fax 83239 0
+ 64 9 488 0234
Email 83239 0
[email protected]
Contact person for scientific queries
Name 83240 0
Jennifer Zhang
Address 83240 0
AFT Pharmaceuticals ltd.
Level 1, 129 Hurstmere Road, Takapuna, Auckland, 0622 New Zealand
Country 83240 0
New Zealand
Phone 83240 0
+ 64 9 488 0232
Fax 83240 0
+ 64 9 488 0234
Email 83240 0
[email protected]

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
No/undecided IPD sharing reason/comment


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.